Healthcare / Drug Manufacturers - Specialty & GenericBSE
$47.06
-0.65 (-1.36%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 26% · confianza 25%
FCF escenarios
weak_data · normalized FCF $13.8M · quality 60.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$3.9B
P/E
29.8x
↑EV/EBITDA
17.8x
↑ROE
17.4%
↑Gross Margin
26.7%
↓Debt/Equity
0.25
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+14.2%
FCF CAGR
-4.2%
FCF margin
0.7%
FCF / Net income
0.11x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.06B · net income $131.2M · FCF $13.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $2.06B | $2.06B | $1.51B | $1.43B | $1.38B |
| Net Income | $131.2M | $131.2M | $100.9M | $82.9M | $72.4M |
| EBITDA | $229.6M | $229.6M | $176.9M | $148.6M | $161.2M |
| EPS | — | — | 1.22 | 1.00 | 0.87 |
| Gross Margin | 26.7% | 26.7% | 28.2% | 17.2% | 18.6% |
| Operating Margin | 6.8% | 6.8% | 7.9% | 7.0% | 5.0% |
| Net Margin | 6.4% | 6.4% | 6.7% | 5.8% | 5.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.25 | 0.25 | 0.24 | 0.15 | 0.22 |
| Current Ratio | 1.66 | 1.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $13.8M | $13.8M | $17.0M | $-404000.00 | $15.7M |
| Returns | |||||
| ROE | 17.4% | 17.4% | 16.2% | 15.8% | 16.5% |
| Valuation | |||||
| P/E | 29.78 | 29.78 | 46.88 | 47.90 | 92.46 |
| EV/EBITDA | 17.76 | 17.76 | 27.51 | 27.28 | 41.96 |
| P/B | 5.17 | 5.17 | 7.57 | 7.59 | 15.23 |
| Growth & Yield | |||||
| Revenue Growth | 36.7% | 36.7% | 5.3% | 3.5% | — |
| EPS Growth | — | — | 22.0% | 14.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-13.0%
Start / end P/E
n/dx → n/dx
EPS bridge
1.22 → n/d
Residual
-13.0%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.